LXRX

0.5031

8.40% 0.039

시장 영업 전: .48 -0.0231 -4.59%

렉시콘 파마슈티컬스 (LXRX)

개요 뉴스 가격 이력 옵션 체인 Financials LXRX 왜 하락? 토론 예측 주식 분할

전일 마감가:

$0.4641

열려 있는:

$0.44

하루 거래량:

16.65M

Relative Volume:

1.23

시가총액:

$181.87M

수익:

$1.21M

순이익/손실:

$-177.12M

주가수익비율:

-0.6289

EPS:

-0.8

순현금흐름:

$-162.37M

1주 성능:

+52.92%

1개월 성능:

-28.08%

6개월 성능:

-68.75%

1년 성능:

-77.24%

1일 변동 폭

$0.4263

$0.52

1주일 범위

$0.325

$0.7072

52주 변동 폭

$0.2836

$2.45

렉시콘 파마슈티컬스 Stock (LXRX) Company Profile

명칭

Lexicon Pharmaceuticals Inc

부문

Healthcare (1161)

산업

Biotechnology (676)

전화

(281) 863-3000

주소

2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS

직원

285

트위터

@LexPharma

다음 수익 날짜

2024-11-06

최신 SEC 제출 서류

LXRX's Discussions on Twitter

LXRX을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
LXRX Lexicon Pharmaceuticals Inc	0.5031	181.87M	1.21M	-177.12M	-162.37M	-0.80
VRTX Vertex Pharmaceuticals Inc	483.49	124.48B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	625.60	67.45B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	583.62	35.60B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	266.83	34.53B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	274.78	29.15B	3.81B	-644.79M	-669.77M	-6.24

렉시콘 파마슈티컬스 Stock (LXRX) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-03-05	다운그레이드	Leerink Partners	Outperform → Market Perform
2024-06-17	개시	H.C. Wainwright	Buy
2024-04-30	개시	Leerink Partners	Outperform
2023-03-07	개시	Jefferies	Hold
2022-08-12	개시	Piper Sandler	Overweight
2021-01-29	업그레이드	JP Morgan	Underweight → Neutral
2021-01-29	다운그레이드	Wedbush	Outperform → Neutral
2020-12-08	업그레이드	Citigroup	Neutral → Buy
2020-11-18	업그레이드	Gabelli & Co	Hold → Buy
2019-12-11	다운그레이드	Gabelli & Co	Buy → Hold
2019-11-08	다운그레이드	Citigroup	Buy → Neutral
2019-09-11	업그레이드	Gabelli & Co	Hold → Buy
2019-07-29	다운그레이드	Stifel	Buy → Hold
2019-03-25	업그레이드	Gabelli & Co	Sell → Hold
2018-07-31	재확인	Stifel	Buy
2018-02-23	다운그레이드	Needham	Buy → Hold
2018-02-14	다운그레이드	JP Morgan	Neutral → Underweight
2017-03-01	재확인	H.C. Wainwright	Buy
2017-03-01	재확인	Wedbush	Outperform
2016-10-07	개시	H.C. Wainwright	Buy
2016-08-05	재확인	Wedbush	Outperform
2016-08-02	개시	Citigroup	Buy
2016-03-02	재확인	Wedbush	Outperform
2015-11-09	재확인	Wedbush	Outperform
2015-09-28	업그레이드	Gabelli & Co	Sell → Hold
2015-09-18	다운그레이드	Gabelli & Co	Hold → Sell
2015-08-10	다운그레이드	JP Morgan	Overweight → Neutral

모두보기

렉시콘 파마슈티컬스 주식(LXRX)의 최신 뉴스

Apr 02, 2025

LXRX Stock Moves Up 30% in a Week: What is Driving This Rally? - MSN

Apr 02, 2025

Lexicon Pharmaceuticals to present at Healthcare Conference - Investing.com India

Apr 02, 2025

Lexicon Pharmaceuticals to present at Healthcare Conference By Investing.com - Investing.com Australia

Apr 02, 2025

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times

Apr 02, 2025

Lexicon Pharma (LXRX) to Present at the 24th Annual Needham Virtual Healthcare Conference - StreetInsider

Apr 02, 2025

Apr 01, 2025

Social Buzz: Wallstreetbets Stocks Mixed Premarket Tuesday; Tesla to Advance, Lexicon Pharmaceuticals to Decline - MarketScreener

Apr 01, 2025

Lexicon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:LXRX) - MarketBeat

Apr 01, 2025

Mar 31, 2025

Novo Nordisk gains rights to novel small molecule inhibitor - European Pharmaceutical Review

Mar 31, 2025

Houston-area company inks massive $1B deal for weight-loss drug - Chron

Mar 31, 2025

Novo Nordisk licenses Lexicon’s preclinical obesity drug in $1B deal - BioWorld MedTech

Mar 31, 2025

US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analyst - Benzinga

Mar 31, 2025

Mar 29, 2025

The Woodlands-based company strikes obesity-drug license deal worth up to $1B - KHOU.com

Mar 29, 2025

Mar 28, 2025

Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade) - Seeking Alpha

Mar 28, 2025

Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1 - Investor's Business Daily

Mar 28, 2025

Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s - MedCity News

Mar 28, 2025

Lexicon Pharmaceuticals, Novo Nordisk strike obesity-drug license deal worth up to $1B - The Business Journals

Mar 28, 2025

Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal - Reuters

Mar 28, 2025

Lexicon Pharmaceuticals: Strategic Partnerships and Pipeline Advancements Drive Buy Rating - TipRanks

Mar 28, 2025

Lexicon Pharma soars as it licenses LX9851 to Novo Nordisk - The Pharma Letter

Mar 28, 2025

Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected - Benzinga

Mar 28, 2025

Lexicon inks $1 billion deal with Novo Nordisk for obesity drug By Investing.com - Investing.com South Africa

Mar 28, 2025

Lexicon stock rises on Novo Nordisk licensing deal (LXRX) - Seeking Alpha

Mar 28, 2025

Sector Update: Health Care Stocks Steady Premarket Friday - MarketScreener

Mar 28, 2025

Lexicon Pharmaceuticals (LXRX) Soars 95% on Novo Nordisk Licensi - GuruFocus.com

Mar 28, 2025

Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk - Benzinga

Mar 28, 2025

Novo Nordisk in licensing deal with Lexiconcould pay up to $1 billion - MarketScreener

Mar 28, 2025

Lexicon Pharmaceuticals Enters License Agreement With Novo Nordisk for Obesity Drug; Shares Jump - Marketscreener.com

Mar 28, 2025

Lexicon inks $1 billion deal with Novo Nordisk for obesity drug - Investing.com Australia

Mar 28, 2025

Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk For LX9851 - Marketscreener.com

Mar 28, 2025

Lexicon Pharma (LXRX) Announces Exclusive License Agreement with Novo Nordisk for LX9851 - StreetInsider.com

Mar 28, 2025

Lexicon's Game-Changing Obesity Drug Catches Novo Nordisk's Eye in Billion-Dollar Deal - Stock Titan

Mar 28, 2025

Mar 27, 2025

Chronic Neuropathic Pain Market to Reach New Heights in Growth - openPR

Mar 27, 2025

Mar 26, 2025

Investors Don't See Light At End Of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Tunnel And Push Stock Down 50% - simplywall.st

Mar 26, 2025

Mar 24, 2025

FDA rejects Lexicon's Zynquista for diabetes, kidney disease - MSN

Mar 24, 2025

Mar 12, 2025

Lexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at StockNews.com - Defense World

Mar 12, 2025

Mar 10, 2025

Piper Sandler Cuts Lexicon Pharmaceuticals (NASDAQ:LXRX) Price Target to $6.00 - Defense World

Mar 10, 2025

Equities Analysts Issue Forecasts for LXRX Q1 Earnings - Defense World

Mar 10, 2025

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives $3.67 Consensus PT from Brokerages - Defense World

Mar 10, 2025

Mar 09, 2025

Lexicon Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Mar 09, 2025

Lexicon Pharmaceuticals Faces Supply Chain Risks Amidst Changing Trade Policies - TipRanks

Mar 09, 2025

Mar 08, 2025

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 08, 2025

Mar 07, 2025

Lexicon Pharmaceuticals’ Mixed Earnings Call: Achievements and Challenges - TipRanks

Mar 07, 2025

LEXICON PHARMACEUTICALS, INC. SEC 10-K Report - TradingView

Mar 07, 2025

Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025 - The Manila Times

Mar 07, 2025

What Analysts Are Saying About Lexicon Pharmaceuticals Stock - Benzinga

Mar 07, 2025